Indaptus Therapeutics saw a significant increase in shares, rising by 26% to $2.63 in premarket trading following the announcement of positive results from the second cohort of its Phase 1 trial for their lead therapeutic candidate, Decoy20.
Broad Immune Response Continues
The biotechnology company reported that patients in the second cohort exhibited a broad immune response similar to the first cohort. These preliminary results were carefully reviewed by Indaptus and an independent Safety Review Committee, leading to the decision to proceed with the trial and enroll patients for multiple doses of Decoy20.
Next Steps in the Trial
The next stage of the trial aims to evaluate the safety of administering Decoy20 multiple times to the same patient. Additionally, the trial will begin to explore the efficacy of Decoy20 across various types of cancer. Animal models have already shown that Decoy20 is safe with multiple dosing schedules.
Immediate Patient Screening
With the recommendation to continue the trial and administer multiple doses of Decoy20, Indaptus has wasted no time and has already begun screening potential patients for enrollment.